Factors for Long-Term Ritodrine Monotherapy in the Treatment of Preterm Labor: A Single-Center Retrospective Study
Abstract
Ritodrine is used to manage threatened preterm labor (TPL) in Japan. While short-term administration is recommended internationally, long-term administration remains the customary practice in Japan, creating a gap in clinical practice between Japan and other regions. This retrospective study aimed to identify the maternal factors associated with long-term administration of ritodrine monotherapy. We reviewed the records of patients who received ritodrine infusion for TPL at the Yamaguchi University Hospital between April 2017 and March 2023. Patients were classified into the long-term monotherapy group (n = 37) if they received ritodrine monotherapy for more than 2 weeks. The non-long-term monotherapy group (n = 102) included patients who received ritodrine monotherapy for less than 2 weeks, required additional tocolytic agents, or discontinued ritodrine due to adverse events. The analysis showed that the white blood cell (WBC) count at treatment initiation was significantly lower in the long-term monotherapy group (p < 0.05). A receiver operating characteristic curve analysis identified a WBC count of 8710 as the cut-off value for predicting long-term administration. Multivariate logistic regression analysis identified a WBC count below 8710 at treatment initiation as an independent factor for the long-term administration of ritodrine infusion (odds ratio: 2.57; 95% confidence interval: 1.12-5.90). Although further validation is required, these findings suggest that the WBC count at the initiation of ritodrine infusion may serve as a potential indicator of long-term ritodrine monotherapy administration in pregnant women with TPL.
Related
- Mortality and clinical outcomes in preterm infants with patent ductus arteriosus according to pharmacological treatment or expectant management: a retrospective cohort study.
- Perinatal and Early Respiratory Factors Associated with Invasive Mechanical Ventilation in Very Preterm Infants: A Retrospective Cohort Study from Kazakhstan
- Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
- Factors Influencing the Treatment Response of Tetracyclines for Papulopustular Rash Induced by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Study.
- Treatment Outcomes and Prognostic Factors in Children with Myeloid Leukemia Associated with Down Syndrome: A Nationwide Polish Retrospective Study
BibTeX
@article{sasaki2026factors,
title = {{Factors for Long-Term Ritodrine Monotherapy in the Treatment of Preterm Labor: A Single-Center Retrospective Study}},
author = {Takaaki Sasaki and Miho Tamura and Atsuyuki Saisyo and Hiroki Hakuno and Susumu Murata and Naoto Okada and Takashi Kitahara},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = oct,
doi = {10.1248/bpb.b26-00136},
url = {https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00136/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Factors for Long-Term Ritodrine Monotherapy in the Treatment of Preterm Labor: A Single-Center Retrospective Study
AU - Takaaki Sasaki
AU - Miho Tamura
AU - Atsuyuki Saisyo
AU - Hiroki Hakuno
AU - Susumu Murata
AU - Naoto Okada
AU - Takashi Kitahara
PY - 2026
DA - 2026/10/28
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b26-00136
UR - https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00136/_article
AB - Ritodrine is used to manage threatened preterm labor (TPL) in Japan. While short-term administration is recommended internationally, long-term administration remains the customary practice in Japan, creating a gap in clinical practice between Japan and other regions. This retrospective study aimed to identify the maternal factors associated with long-term administration of ritodrine monotherapy. We reviewed the records of patients who received ritodrine infusion for TPL at the Yamaguchi University Hospital between April 2017 and March 2023. Patients were classified into the long-term monotherapy group (n = 37) if they received ritodrine monotherapy for more than 2 weeks. The non-long-term monotherapy group (n = 102) included patients who received ritodrine monotherapy for less than 2 weeks, required additional tocolytic agents, or discontinued ritodrine due to adverse events. The analysis showed that the white blood cell (WBC) count at treatment initiation was significantly lower in the long-term monotherapy group (p < 0.05). A receiver operating characteristic curve analysis identified a WBC count of 8710 as the cut-off value for predicting long-term administration. Multivariate logistic regression analysis identified a WBC count below 8710 at treatment initiation as an independent factor for the long-term administration of ritodrine infusion (odds ratio: 2.57; 95% confidence interval: 1.12-5.90). Although further validation is required, these findings suggest that the WBC count at the initiation of ritodrine infusion may serve as a potential indicator of long-term ritodrine monotherapy administration in pregnant women with TPL.
SN - 1347-5215
SN - 0918-6158
ER -